viewOpen Orphan PLC

Open Orphan 'on target to be profitable' and plans to end year 'with substantially more cash'

Open Orphan's (LON:ORPH) Cathal Friel talks to Proactive London after publishing their six months results - which he says reveal they are 'on target to be profitable' and plans to end year 'with substantially more cash'.

Cash and cash equivalents at half year end were £14.7m with revenue of £7.1m, with a continued focus on delivering larger contracts.

Friel also talks through the £4.3 million contract with a global top ten vaccine company that was revealed earlier in the week.

And he hints on 'advanced negotiations with various parties' for a Coronavirus challenge study in the UK.

Quick facts: Open Orphan PLC

Price: 23 GBX

Market: AIM
Market Cap: £154.97 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...


Open Orphan present at the Proactive One2one virtual investment forum

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual October Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

1 week, 6 days ago

2 min read